Ajay J. Kirtane, MD, SM, is Professor of Medicine at Columbia University Irving Medical Center and Director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center. Dr. Kirtane is an internationally-renowned leader in Interventional Cardiology, specializing in the care of patients with complex coronary and peripheral vascular disease. In this video, he speaks about A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN).
A Summary Synopsis:
RADIANCE-HTN is a two-cohort, randomized, double-blind, sham-controlled study (TRIO and SOLO) that aims to demonstrate the efficacy and document the safety of the Paradise Renal Denervation System in two hypertensive populations.
The RADIANCE Solo cohort will consist of subjects with essential hypertension who are controlled on one or two antihypertensive medications or who are uncontrolled on 0-2 antihypertensive medications, whereas the RADIANCE Trio cohort will consist of subjects with treatment resistant hypertension who are on at least three antihypertensive medications. Before randomization, subjects will be hypertensive in the absence of hypertension medication (SOLO) or despite a stabilized, single tablet, triple, fixed dose antihypertensive treatment regimen (TRIO).